Literature DB >> 8644983

The long-term clinical course of acute deep venous thrombosis.

P Prandoni1, A W Lensing, A Cogo, S Cuppini, S Villalta, M Carta, A M Cattelan, P Polistena, E Bernardi, M H Prins.   

Abstract

BACKGROUND: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented.
OBJECTIVE: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis.
DESIGN: Prospective cohort study.
SETTING: University outpatient thrombosis clinic. PATIENTS: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis. MEASUREMENTS: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated.
RESULTS: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1).
CONCLUSION: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644983     DOI: 10.7326/0003-4819-125-1-199607010-00001

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  302 in total

Review 1.  Preventing thromboembolic complications in older orthopaedic surgery patients: interventions and outcomes.

Authors:  J W Eikelboom; J S Ginsberg
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

Review 2.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

3.  Thrombophilia testing: what do we think the tests mean and what should we do with the results?

Authors:  T Baglin
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

4.  Should we look further for cancer in a patient with venous thromboembolism?

Authors:  D E Arterburn; W S Richardson
Journal:  West J Med       Date:  2000-05

5.  Optimizing the duration of anticoagulation therapy for venous thrombosis.

Authors:  S Solymoss
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

6.  Radiofrequency radiation exposure and other environmental concerns.

Authors:  R House
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

7.  Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: a nested case-control study.

Authors:  Aneel A Ashrani; Marc D Silverstein; Thom W Rooke; Brian D Lahr; Tanya M Petterson; Kent R Bailey; L Joseph Melton; John A Heit
Journal:  Vasc Med       Date:  2010-10       Impact factor: 3.239

Review 8.  Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors:  Hikmat Abdel-Razeq; Asem Mansour
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

Review 9.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.